Prestige Biologics프레스티지바이오로직스

Prestige Biologics shows steep losses and a share price down sharply over the past year, with revenue rising from a small base.

Prestige Biologics is a Korean CDMO for biopharmaceuticals with stated capacity of 154,000 liters and several GMP certifications. For FY2025 it reported revenue of ₩12.5B against an operating loss of ₩33.7B and a net loss of ₩27.5B, with cash of ₩1.6B against borrowings of ₩14.2B. The shares closed at ₩1,294 on 2026-10-15, about 60% below their 52-week high of ₩3,850.

What stands out

• Revenue rose to ₩12.5B in FY2025 from ₩2.2B in FY2024, but operating losses remain far larger than revenue, with an operating margin of -268.7%.
• Free cash flow was negative ₩23.5B on a trailing basis, and the data shows borrowings of ₩14.2B against cash of ₩1.6B.
• Liabilities to equity stood at 99.9%, and the price-to-book ratio is 0.7 while price-to-sales is 8.0; no P/E is shown because earnings are negative.
• Recent filings include a withdrawn share consolidation decision on 2026-09-30, an annual report and audit report filed in September 2026, and amended major supply contract filings.
• No recent news headlines are included in the data, and foreign ownership and investor flow figures are not available.

What to watch

• The next filed results and whether losses narrow relative to revenue, given the reported cash and borrowing position.
• The status of the withdrawn share consolidation decision and any further amendments to filings, including the major supply contract.
• Any filings on financing, debt or capital changes, since the data shows cash well below borrowings and negative free cash flow.